



COMPARATIVE BIOSCIENCES, INC.

A TRANSLATIONAL APPROACH TO PRECLINICAL RESEARCH

Freedom
from Insulin



New Hope for Diabetes Patients


CBI, leaders in Stem Cell Pharmacology and GLP Toxicology, congratulates our Friends and Colleagues at VIACYTE, INC on their FDA success.



CBI is the industry leader in conducting difficult and complicated IND enabling and research studies with Stem Cells and Stem-Cell Device combination studies. We have conducted these complex studies in multiple species and for durations exceeding 1.5 years

CONGRATULATIONS COMPARATIVE BIOSCIENCES, INC.

[View CIRM Press Release](#)



Type 1 Diabetes Treatment Funded by California Stem Cell Agency Cleared To Begin Clinical Trial

August 19, 2014

San Francisco, CA – ViaCyte Inc., a regenerative medicine company headquartered in San Diego, has been given approval to begin a clinical trial for a promising treatment for type 1 diabetes, a program that is funded by the California Institute for Regenerative Medicine (CIRM), California's stem cell agency.

The Food and Drug Administration (FDA) gave ViaCyte the go-ahead after reviewing their application for an Investigational New Drug application ("IND"). The phase 1/2 clinical trial will see if their VC-01™ product candidate is safe and shows preliminary evidence of being beneficial to patients.

Contact us for more information and validation data.

[CLICK HERE:
Stem Cell Research](#)

[CLICK HERE:
Pharmacology](#)

[CLICK HERE:
Antibacterial Research & Consulting](#)